Accelerated approval for palbociclib in combination with letrozole (Femara®), an aromatase inhibitor, for the treatment of advanced ER+HER2- breast cancer was granted in 2015 based on the results of the Phase II PALOMA-1 trial. The gene discussed is ESR1; the disease is breast carcinoma.